APhA--APRS {#sec1}
==========

Dedicated delegates rise to the challenge {#sec1.1}
-----------------------------------------

Nau

It has been a wild ride for all of us these last few months, but APhA has been able to continue its work amid the chaos of coronavirus disease (COVID-19). When faced with the unprecedented challenge of travel restrictions that prevented a live Annual Meeting, the APhA staff and Academy officers quickly rallied to create a virtual experience. For the first time in the history of the Association, we conducted a virtual House of Delegates (HOD).

In preparing for the HOD, we asked the APhA--APRS delegates to participate in 2 virtual caucuses. I was excited to find that nearly all of our delegates were able to join both caucuses and the HOD live session. I truly appreciate the dedication of our delegates!

Given the challenge of conducting the business of the HOD in a virtual session, we had to modify the rules and schedule of the HOD. One of the biggest changes was to allow online voting by delegates before the HOD session. The delegates voted through a secure Web portal on the 3 policies recommended by the APhA Policy Committee, as well as 12 New Business Items (NBIs) submitted by members. These 15 policies under consideration included 53 unique statements on which the delegates voted. All but 4 of the statements received a majority vote in favor of the statement and were adopted as APhA policy.

COVID-19 NBIs {#sec1.2}
-------------

During the live virtual session of the HOD on March 20 afternoon, the delegates considered 3 urgent NBIs submitted by the APhA Board of Trustees. These NBIs all pertained to the COVID-19 pandemic, and 2 of the policies were passed with strong support.

The first of these 2 policies addressed the need for regulators to recognize pharmacists as "front-line providers" so that personal protective equipment would continue to be made available to pharmacists during the pandemic. The second of the policies called on federal and state authorities to aggressively enforce laws on price gouging and false or misleading claims about pharmaceuticals, tests, and other products. The third proposal was referred to the Board of Trustees and ultimately resulted in a joint statement from APhA, the American Medical Association, and the American Society of Health-System Pharmacists to address the concerns of inappropriate ordering, prescribing, and dispensing of medications and medical supplies.

Additional policy discussion {#sec1.3}
----------------------------

Another NBI of note was the call for APhA to support state regulations that allow pharmacy technicians to administer vaccines. The early research on technician administration indicates that well-trained, certified technicians can safely administer vaccines. However, there is a need for more research to substantiate the safety and efficiency of expanding immunization roles for technicians and to delineate the most appropriate model for pharmacists' and technicians' roles in immunizations, as well as optimal design of regulatory language to enable greater immunization access while ensuring the safety of patients.

Yet another NBI of interest to scientist members of APhA focused on the integration of digital health technologies in pharmacy practice. Given the sudden shift toward telehealth and digital technologies that has been driven by the pandemic, I think there is a great need for research on the optimal models for the use of these technologies. I also believe that artificial intelligence (AI) will be a notable disruptor of current health care models over the next decade, and the impact on pharmacists' roles and employment should not be underestimated. Consequently, I call on my colleagues in APhA--APRS to work with our counterparts in APhA--APPM to study new models of care that seek an optimal mix of human interaction and AI support.

In addition to the debate on the NBIs, the delegates further amended the wording of the first policy, which was approved through online voting, on the topic of "Protecting Pharmaceuticals as a Strategic Asset." It was prescient that the APhA Policy Committee developed this policy in the year before the pandemic.

One of the key factors that prompted this proposed policy was the recognition that many drug products used in the United States are manufactured outside of our country, and many of the active pharmaceutical ingredients used in US-manufactured products are sourced from foreign countries. Thus, economic or political crises (or pandemics) across the globe may interfere with our ability to obtain sufficient supplies of critical medications. The policy supports APhA's advocacy of protecting the supply chain of pharmaceuticals to ensure that the quality and quantity of critical medications are maintained.

Given that the current pandemic is expected to continue in waves over the foreseeable future, it is possible that we will need to hold future sessions of the APhA HOD in a virtual manner. APhA staff welcome the feedback of all delegates and members to optimize the effectiveness and efficiency of HOD activities.

Details on all of the HOD actions and the resulting policies are available at: [www.pharmacist.com/sites/default/files/audience/2020_Report_of_the_APhA_Virtual_House_of_Delegates-FINAL_3.pdf](http://www.pharmacist.com/sites/default/files/audience/2020_Report_of_the_APhA_Virtual_House_of_Delegates-FINAL_3.pdf){#intref0010}.
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